Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC)

NCT: NCT05911633 · RECRUITING

NCT IDNCT05911633
StatusRECRUITING
Start Date2024-02-27
Completion2027-12-30
SponsorTerumo Europe N.V. (INDUSTRY)
First posted
Last updated

Brief Summary

The primary objective of the study is to confirm safety and technical success of BioPearl™ microspheres loaded with Doxorubicin in the treatment of unresectable hepatocellular carcinoma (HCC). The secondary objective of the study is to investigate the efficacy of BioPearl™ microspheres loaded with Doxorubicin in the treatment of subjects with unresectable HCC.

Frequently Asked Questions

What is BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC)?

BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC) is a clinical trial registered under NCT05911633. Current status: RECRUITING.

What is the status of NCT05911633?

The current status of NCT05911633 (BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC)) is: RECRUITING.

When did BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC) start?

BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC) started on 2024-02-27.

Related Devices

K161606Syringe with fixed needle - For use only with GONAL-F Multi-Dose 600 I/U mL FSHTerumo Europe N.V. K192057K-Pack II Needle - 27G x 1/2” Extra Thin Wall, K-Pack II Needle - 27G x 1/2” Ultra Thin Wall, K-Pack II Needle - 30G x 1/2” Extra Thin Wall, K-Pack II Needle - 30G x 1/2” Ultra Thin WallTerumo Europe N.V. K212095SurGuard3 Safety Hypodermic NeedleTerumo Europe N.V. K230951Terumo Injection Filter Needle (NF-3013RBKE05M)Terumo Europe N.V. K24330927G x 1/2 TW K-Pack Surshield Needle (KN-S2713RBT)Terumo Europe N.V.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑